BRCA Testing : Episode 3

Video

Preparing for Your BRCA Testing

Related Videos
a man and a woman in front of a dark blue background
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
a man and a woman in front of a dark blue background
Delving Into Clinical Research For Patients With Breast Cancer
a man and a woman in separate boxes in front of a dark blue background
Clinical Trials to Watch in Triple-Negative Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Improving Efficacy, Minimizing Toxicity in Chemotherapy For Breast Cancer
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Long-Term Patient Care Focuses on Precision-Based Therapy in Breast Cancer
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Improving Treatment Access to Innovative Therapies in Breast Cancer
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Expert Expands on Side Effects Related to ADC Treatment in Breast Cancer
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
What Patients With Breast Cancer Can Learn From Germline Testing
Related Content
green background with white text indicating FDA Approval, What You Need to Know
March 8th 2025

FDA Approves Biosimilars for Cancer-Related Skeletal Events

Alex Biese
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of a woman with red hair.
March 5th 2025

Becoming a Better Version of Me After Breast Cancer

Bonnie Annis
A revelation has given me perspective for the New Year, inspiring me to embrace change, set new goals and upgrade myself to a better version in 2025.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of woman with brown hair.
March 4th 2025

Breast Cancer And Depending On The Kindness Of Strangers

Laura Yeager
I reflect on my unexpected bond with a neighbor during my breast cancer treatment, finding comfort in his company when I needed someone to talk to.
Camizestrant combo had a statistically significant and clinically meaningful improvement in PFS in advanced breast cancer; © Pixel-Shot - stock.adobe.com
March 1st 2025

Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

Ryan Scott
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.